Author:
Kobayashi Masato,Tsujiuchi Takafumi,Okui Yuya,Mizutani Asuka,Nishi Kodai,Nakanishi Takeo,Nishii Ryuichi,Fukuchi Kazuki,Tamai Ikumi,Kawai Keiichi
Funder
Grants-in-Aid for Scientific Research
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference23 articles.
1. Lockhart A, Tirona L, Kim R. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2003;2:685–98.
2. Kailasnath P, Sinusas AJ. Technetium-99m-labeled myocardial perfusion agents: are they better than thallium-201? Cardiol Rev. 2001;9(3):160–72.
3. Schillaci O, Spanu A, Madeddu G. [99mTc]sestamibi and [99mTc]tetrofosmin in oncology: SPECT and fusion imaging in lung cancer, malignant lymphomas and brain tumors. Q J Nucl Med Mol Imaging. 2005;49(2):133–44.
4. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergün EL, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med. 1998;39:228–34.
5. Kurata S, Ushijima K, Kawahara A, Kaida H, Kawano K, Hirose Y, et al. Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study. Ann Nucl Med. 2015;29:643–9.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献